Anti-hCD20-hIgM

InvivoGen Kontakt z doradcą
Human CD20 (Rituximab) antibody - Human IgM
Anti-hCD20-hIgM

Anti-hCD20-hIgM features the constant region of the human IgM isotype and the variable region of rituximab.

Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes.

Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity.

Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukaemia.

Anti-hCD20-hIgM was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein L.

Podobne produkty

Mouse IgG2a Control

Mouse IgG2a Control

InvivoGen
Więcej
Anti-Flagellin

Anti-Flagellin

InvivoGen
Więcej
Anti-hCTLA-4

Anti-hCTLA-4

InvivoGen
Więcej